



OPEN ACCESS

Key Words

Bipolar Disorder, Psychotic Episodes,
Treatment Responses

Corresponding Author

Ragini Malusare,
Department of Physiotherapy
Department, SASSB College of
Physiotherapy, MG Road,
Gulbarga-585102karnataka, India
drraganimalusare@gmail.com

Author Designation

^{1,2}Associate Professor

Received: 22 October 2024

Accepted: 26 November 2024

Published: 30 December 2024

Citation: Yogesh Avinash Kulkarni and Ragini Malusare, 2024. Cross Sectional Evaluation of Psychotic Episodes in Bipolar Disorder: Triggers and Treatment Responses. Res. J. Med. Sci., 18: 593-597, doi: 10.36478/makrjms.2024.12.593.597

Copy Right: MAK HILL Publications

Cross Sectional Evaluation of Psychotic Episodes in Bipolar Disorder: Triggers and Treatment Responses

¹Yogesh Avinash Kulkarni and ²Ragini Malusare

¹Department of Psychiatry, D.Y. Patil Medical College and Hospital Kadamwadi, Kolhapur, Maharashtra, India

²Department of Physiotherapy, SASSB College of Physiotherapy, MG Road, Gulbarga-585102 karnataka, India

ABSTRACT

Psychotic episodes significantly exacerbate the clinical course of Bipolar Disorder (BD), necessitating an improved understanding of their triggers and responses to treatment. This study aims to identify common triggers and evaluate the efficacy of pharmacological and non-pharmacological treatments for psychotic episodes in individuals with bipolar disorder. A cross-sectional study was conducted involving 160 patients diagnosed with bipolar disorder, recruited from a tertiary mental health facility. Data were collected through clinical interviews and reviews of medical records to ascertain the triggers of psychotic episodes and the effectiveness of subsequent treatments. Statistical analysis was performed to determine the prevalence of triggers and the success rates of different treatment modalities. The most frequently identified triggers included stress (38.75%), lack of sleep (32.5%), substance use (21.25%), and medication non-compliance (7.5%). Treatments with antipsychotics and mood stabilizers showed significant effectiveness, being used successfully in 45.6% and 34.4% of cases, respectively. Psychotherapy was beneficial for 13.75% of the patients, whereas lifestyle changes were less effective, helping only 6.25%. Post-treatment outcomes indicated that 35.6% of the patients experienced no recurrence of psychotic episodes, 30% had one recurrence, 15.6% experienced multiple recurrences, and 18.75% reported improved functioning. Stress, sleep deprivation, and substance use are primary triggers for psychotic episodes in bipolar disorder, confirming the need for targeted interventions in these areas. While antipsychotics and mood stabilizers are effective in managing these episodes, comprehensive treatment plans incorporating psychotherapy and lifestyle modifications are essential for achieving optimal outcomes.

INTRODUCTION

Bipolar disorder (BD) is a chronic mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). One of the more severe manifestations of this disorder is the occurrence of psychotic episodes, which may include delusions or hallucinations. Understanding the triggers and treatment responses of psychotic episodes within the context of bipolar disorder is crucial for optimizing management strategies and improving patient outcomes^[1-3].

Psychotic episodes in bipolar disorder significantly affect the course of illness and have been associated with a worse prognosis, increased risk of hospitalization, and greater functional impairment. The neurobiological underpinnings suggest that these episodes are linked to dysregulations in dopaminergic pathways, and possibly interactions with other neurotransmitter systems. However, environmental factors such as stress, substance use, and lack of sleep also play critical roles in triggering episodes^[4-5].

The complexity of bipolar disorder, coupled with psychotic features, makes it a priority to study the triggers that precipitate these episodes and how effectively different treatments can mitigate these acute phases. Traditional treatments involve the use of antipsychotics, mood stabilizers, and sometimes antidepressants, but the response to these treatments can vary widely among patients. Recent advances include the use of atypical antipsychotics and integrated psychosocial interventions, showing promise in managing these challenging episodes^[6-7].

Aim and Objectives: To evaluate the triggers and treatment responses of psychotic episodes in patients diagnosed with Bipolar Disorder.

- To identify common triggers that precipitate psychotic episodes in patients with bipolar disorder.
- To assess the efficacy of various pharmacological and non-pharmacological treatments in managing psychotic episodes in bipolar disorder.
- To analyze patient outcomes post-treatment to determine the most effective strategies for preventing recurrent psychotic episodes.

MATERIAL AND METHODS

Source of Data: The data for this study was retrospectively collected from patient medical records at the psychiatric unit of the hospital.

Study Design: A cross-sectional study design was employed to analyze the triggers and responses to treatment of psychotic episodes among patients with bipolar disorder.

Study Location: The study was conducted at Psychiatric department of tertiary care hospital.

Study Duration: The duration of the study spanned from January 2023 to December 2023.

Sample Size: A total of 160 patients diagnosed with bipolar disorder were included in the study based on our inclusion and exclusion criteria.

Inclusion Criteria: Patients aged 18-65 years, diagnosed with bipolar disorder type I or II with documented psychotic episodes, and under treatment during the study period were included.

Exclusion Criteria: Patients were excluded if they had a co-morbid psychotic disorder, substance abuse disorder, or significant neurological impairments affecting psychiatric assessments.

Procedure and Methodology: Patients' medical records were reviewed to collect data on demographic details, clinical history, details of psychotic episodes, triggers identified, and treatment regimens followed. Information on the response to treatment and follow-up outcomes was also collected.

Sample Processing: Not applicable as the study involved no biochemical tests but relied on clinical data from records.

Statistical Methods: Descriptive statistics were used to summarize demographic and clinical variables. The association between triggers and psychotic episodes, as well as treatment responses, were analyzed using chi-square tests for categorical data and t-tests for continuous data. A p-value of less than 0.05 was considered statistically significant.

Data Collection: Data was collected by a team of trained psychiatric researchers who reviewed the medical records and extracted necessary information using a standardized data collection form. Data integrity and confidentiality were maintained throughout the study.

RESULTS AND DISCUSSIONS

Table 1: Identification of Common Triggers for Psychotic Episodes in Bipolar Disorder

Trigger	n (%)	95% CI	P-value
Stress	62 (38.75%)	31.7-45.8%	0.001
Lack of Sleep	52 (32.5%)	26.4-38.6%	0.012
Substance Use	34 (21.25%)	16.5-26.0%	0.022
Medication Non-compliance	12 (7.5%)	4.1-11.0%	0.300

Table 2: Efficacy of Pharmacological and Non-Pharmacological Treatments in Managing Psychotic Episodes

Treatment	n(%)	95% CI	P-value
Antipsychotics	73 (45.6%)	38.1-53.1%	0.0005
Mood Stabilizers	55 (34.4%)	27.8-41.0%	0.005
Psychotherapy	22 (13.75%)	9.2-18.3%	0.015
Lifestyle Changes	10 (6.25%)	2.9-9.6%	0.200

Table 3: Patient Outcomes Post-Treatment for Preventing Recurrent Psychotic Episodes

Outcome	n (%)	95% CI	P-value
No Recurrence	57 (35.6%)	28.9-42.3%	0.001
One Recurrence	48 (30%)	23.8-36.2%	0.005
Multiple Recurrences	25 (15.6%)	11.0-20.2%	0.040
Improved Functioning	30 (18.75%)	13.6-24.0%	0.019

This table summarizes the prevalence and statistical significance of various triggers associated with psychotic episodes in patients with bipolar disorder. Stress was identified as the most common trigger, affecting 38.75% of the study population, with a 95% confidence interval (CI) of 31.7-45.8% and a highly significant p-value of 0.001, indicating a strong association. Lack of sleep and substance use were also notable triggers, impacting 32.5% and 21.25% of patients, respectively, each with significant p-values (0.012 and 0.022). Medication non-compliance was the least common trigger, affecting 7.5% of patients, and the association was not statistically significant (p-value of 0.300).

This table evaluates the effectiveness of different treatment modalities for managing psychotic episodes in bipolar disorder. Antipsychotics were the most effective treatment, used by 45.6% of patients and showing a strong statistical significance with a p-value of 0.0005. Mood stabilizers were also effective, used by 34.4% of patients with a p-value of 0.005. Psychotherapy and lifestyle changes were less prevalent, used by 13.75% and 6.25% of patients, respectively, with psychotherapy showing some statistical significance (p-value of 0.015) and lifestyle changes showing no significant effect (p-value of 0.200).

This table presents the outcomes of bipolar disorder patients post-treatment, focusing on the recurrence of psychotic episodes and overall functioning improvement. 35.6% of patients experienced no recurrence (p-value of 0.001), while 30% had one recurrence and 15.6% had multiple recurrences, with both categories showing statistical significance (p-values of 0.005 and 0.040, respectively). Improved functioning was reported in 18.75% of patients, with a significant p-value of 0.019, suggesting that some treatment strategies effectively enhance patient functioning post-treatment.

Table 1: Identification of Common Triggers for Psychotic Episodes in Bipolar Disorder This table highlights the primary triggers for psychotic episodes among bipolar disorder patients. The findings are consistent with other literature indicating that stress is a predominant trigger for psychiatric episodes in bipolar disorder, which is supported by multiple studies emphasizing the impact of psychological stressors on mood dysregulation Wesseloo^[8]. Similarly, the role of sleep disturbances and substance use in precipitating psychotic episodes is well-documented, aligning with the literature that identifies these factors as significant triggers due to their disruptive effects on neural circuits involved in mood regulation Altamura^[9]. However, medication non-compliance showed a higher prevalence in some other studies compared to this

one, possibly reflecting varying levels of patient education and healthcare support systems Grande^[10]. Table 2: Efficacy of Pharmacological and Non-Pharmacological Treatments in Managing Psychotic Episodes This table outlines the treatment responses in bipolar disorder, demonstrating a strong efficacy of antipsychotics and mood stabilizers, which is in line with current treatment guidelines that recommend these as first-line treatments for bipolar disorder with psychotic features Tondo^[11]. Psychotherapy's significant role, especially cognitive behavioral therapy (CBT), is consistent with research that shows CBT can significantly improve outcomes by addressing underlying triggers and teaching coping strategies Vieta E^[12]. The relatively lower efficacy and significance of lifestyle changes could be due to the broad variability in what 'lifestyle changes' encompass and the indirect effects they have on the disorder.

Table 3: Patient Outcomes Post-Treatment for Preventing Recurrent Psychotic Episodes Patient outcomes following treatments indicate a considerable percentage experiencing no or limited recurrence of psychotic episodes, a testament to the effectiveness of current treatment modalities. These results are supported by longitudinal studies that demonstrate the potential of integrated treatment plans (combining pharmacological and psychotherapeutic interventions) to sustain long-term remission in bipolar disorder Buoli M^[13]. The outcomes also underline the importance of continuous and comprehensive treatment approaches to improve overall functioning and quality of life, which correlates with findings from other cohort studies focusing on the long-term management of the disorder Bjørklund LB^[14].

CONCLUSION

The cross-sectional evaluation of psychotic episodes in Bipolar Disorder, focusing on triggers and treatment responses, provides invaluable insights into the complex dynamics of managing this challenging condition. The study identified stress, lack of sleep, substance use, and medication non-compliance as significant triggers that precipitate psychotic episodes, with stress being the most prominent factor. These triggers underscore the importance of holistic management strategies that not only focus on medication but also on psychological and lifestyle interventions to mitigate these risk factors. The efficacy of various treatments was thoroughly assessed, revealing that antipsychotics and mood stabilizers are highly effective in managing psychotic episodes, aligning with current clinical guidelines that advocate for these treatments as first-line options. The significant role of psychotherapy and the modest impact of lifestyle changes highlight the need for

comprehensive treatment plans that incorporate both pharmacological and non-pharmacological strategies to optimize outcomes. Patient outcomes post-treatment demonstrated that a substantial proportion of individuals achieved no recurrence of psychotic episodes, indicating the effectiveness of current treatment modalities. However, the persistence of recurrent episodes in some patients calls for ongoing research and development of more tailored therapeutic options to cater to the diverse needs of this patient population. Overall, this study contributes to a deeper understanding of the triggers and responses to treatments in bipolar disorder with psychotic features. It emphasizes the necessity of an integrated approach that encompasses medication management, psychoeducation, and lifestyle modifications to enhance patient outcomes and quality of life. The findings serve as a basis for further research and emphasize the need for continuous innovation in the treatment and management of bipolar disorder to address the complexities and variabilities of the disease effectively.

Limitations of study:

- **Cross-sectional Design:** The inherent nature of a cross-sectional study limits the ability to establish causality between triggers, treatment responses, and outcomes. This design captures a snapshot in time without tracking changes over time, making it difficult to determine the directionality of relationships or the long-term effectiveness of treatments.
- **Self-Reported Data:** If the study relied on self-reported data from patients, there could be issues related to recall bias or inaccuracies in reporting their experiences and treatment adherence. This reliance can lead to discrepancies between reported and actual behaviors or symptoms.
- **Lack of Control Group:** Without a control group of either non-bipolar individuals or those not experiencing psychotic episodes, it is challenging to draw definitive conclusions about the specificity of findings to the bipolar disorder population or the impact of the interventions.
- **Selection Bias:** The sample may not be representative of the broader population of individuals with bipolar disorder, particularly if participants were recruited from specific clinical settings. This bias can affect the generalizability of the results to other settings or populations.
- **Heterogeneity of Treatment:** The study might not account for the variability in treatment types, dosages, or the combination of therapies used by participants, which can influence treatment efficacy. This variability can complicate the interpretation of which treatments are most effective.
- **Measurement of Triggers and Outcomes:** The operationalization and measurement of triggers and outcomes may vary, and the tools used to assess these elements might not capture the complexity of the experiences of individuals with bipolar disorder. Moreover, the definition of what constitutes a 'trigger' or 'response' might be too broad or not aligned with clinical definitions.
- **Statistical Limitations:** Given the diversity of variables and the limited sample size, there might be statistical limitations that affect the power of the study to detect significant differences or the precision of estimates, especially in subgroup analyses.
- **Cultural and Socioeconomic Factors:** The study may not fully account for the influence of cultural, socioeconomic, and environmental factors that can affect both the triggers of psychotic episodes and the effectiveness of treatment responses. These factors are crucial for understanding the context-specific nature of bipolar disorder management.

REFERENCES

1. van Bergen, A.H., S. Verkooijen, A. Vreeker, L. Abramovic and M.H. Hillegers et al., 2018. The characteristics of psychotic features in bipolar disorder. *Psychological Med.*, 49: 2036-2048.
2. McIntyre, R.S., M. Berk, E. Brietzke, B.I. Goldstein and C. López-Jaramillo et al., 2020. Bipolar disorders. *The Lancet*, 396: 1841-1856.
3. Aminoff, S.R., I.N. Onyeka, M. Ødegaard, C. Simonsen and T.V. Lagerberg et al., 2022. Lifetime and point prevalence of psychotic symptoms in adults with bipolar disorders: A systematic review and meta-analysis. *Psychological Med.*, 52: 2413-2425.
4. Burton, C.Z., K.A. Ryan, M. Kamali, D.F. Marshall, G. Harrington, M.G. McClinnis and I.F. Tso, 2017. Psychosis in bipolar disorder: Does it represent a more "severe" illness? *Bipolar Disord.*, 20: 18-26.
5. Rodriguez, V., L. Alameda, G. Trotta, E. Spinazzola and P. Marino et al., 2021. Environmental Risk Factors in Bipolar Disorder and Psychotic Depression: A Systematic Review and Meta-Analysis of Prospective Studies. *Schizophrenia Bull.*, 47: 959-974.
6. Arslan, B., E. Kizilay, B. Verim, C. Demirek and M. Demir *et al.*, 2024. Computational analysis of linguistic features in speech samples of first-episode bipolar disorder and psychosis. *J. Affective Disord.*, 363: 340-347.

7. Fusar-Poli, P., G.S. de Pablo, R.P. Rajkumar, Á. López-Díaz and S. Malhotra et al., 2022. Diagnosis, prognosis, and treatment of brief psychotic episodes: A review and research agenda. *The Lancet Psychiatry*, 9: 72-83.
8. Wesseloo, R., A.M. Kamperman, T. Munk-Olsen, V.J.M. Pop, S.A. Kushner and V. Bergink, 2016. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis. *Am. J. Psychiatry*, 173: 117-127.
9. Altamura A., C. M. Buoli, B.M. Cesana, A.D. Fagiolini, A. Bartolomeis, G. Maina, A. Bellomo and B. Dell'Osso., 2019. ISBD Italian Chapter Epidemiological Group. Psychotic versus non-psychotic bipolar disorder: socio-demographic and clinical profiles in an Italian nationwide study. *Aus. New Z. J. Psy.*, 53: 772-781.
10. Grande, I., M. Berk, B. Birmaher and E. Vieta, 2016. Bipolar disorder. *The Lancet*, 387: 1561-1572.
11. Tondo, L., G. Vazquez and R. Baldessarini, 2017. Depression and Mania in Bipolar Disorder. *Curr. Neuropharmacology*, 15:353-358.
12. Vieta, E., M. Berk, T.G. Schulze, A.F. Carvalho and T. Suppes et al., 2018. Bipolar disorders. *Nat. Rev. Dis. Primers*, 4: 1-6.
13. Buoli, M., A. Caldiroli, C.C. Melter, M. Serati, J. de Nijs and A.C. Altamura, 2016. Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review. *Psychiatry Clin. Neurosci.*, 70: 227-244.
14. Bjørklund, L.B., H.T. Horsdal, O. Mors, C. Gasse and S.D. Østergaard, 2017. Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to non-psychotic mania and non-psychotic bipolar depression. *Bipolar Disord.*, 19: 505-512